10-18-07



Express Mail No.: *EV 913 329 673 US* 

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Coleman et al.

Application No.: 10/573,905

371(c) Date: May 30, 2006

For: TISSUE PROTECTIVE CYTOKINES FOR THE

TREATMENT AND PREVENTION OF SEPSIS

AND THE FORMATION OF ADHESIONS

Confirmation No.: 2092

Art Unit: 1647

Examiner: To Be Assigned

Attorney Docket No.: 10165-042-999

(Formerly: WP03-1A04-US)

#### REQUEST FOR CORRECTION OF FILING RECEIPT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Enclosed please find two copies of the Filing Receipt for the above-identified application. Please note the correction in red ink on one of the copies of the Filing Receipt.

Specifically, the entry in the field of the Filing Receipt entitled "Applicant(s)" should read as follows:

> Michael Brines, Woodbridge, CT; Anthony Cerami, Somers, NY; Thomas Coleman, Mt. Kisco, NY; Osman Yilmaz, Gottepe, TURKEY;

Support for the listed inventors can be found in the executed Declaration that was filed concurrently with the present application on March 29, 2006 and the accompanying Application Data Sheet (copies of which are enclosed).

It is estimated that no fee is required for correction of the Filing Receipt. However, should the Patent Office determine otherwise, please charge the necessary fee to Jones Day Deposit Account No. 50-3013. A duplicate of this sheet is enclosed for accounting purposes.

Respectfully submitted, by: School Harhick Ray. No. 52, 413

Laceta A. Corossi 30,742

Date:

October 16, 2007

Laura A. Coruzzi

JONES DAY

222 East 41st Street

New York, New York 10017 Telephone Number: 212-326-3939

Fax Nos.: 212-869-9741/8864



INITED STATES PATENT AND TRADEMARK OFFICE

OCT 16 2007

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS

010165-0042-999 Alexandria, Virginia 22313-1450

 APPL NO.
 FILING OR 371(c) DATE
 ART UNIT
 FIL FEE REC'D
 ATTY DOCKET NO
 TOT CLMS
 IND CLMS

 10/573,905
 05/30/2006
 1647
 1730
 WP03-1 A04-US
 36
 4

**CONFIRMATION NO. 2092** 

61297 WARREN PHARMACEUTICALS, INC 712 KITCHAWAN ROAD OSSINING, NY 10562 FILING RECEIPT
\*OC000000022649269\*

Date Mailed: 03/13/2007

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Michael Brines, Woodbridge, CT, Anthony Gerami, Somers, My; Thomas Coleman, Mt. Kisco, NY; Osman, Yilmaz, Gottepe, TURKEY;

**Assignment For Published Patent Application** 

The Kenneth S. Warren Institute, Inc., Ossining, NY Warren Pharmaceuticals, Inc., Ossining, NY

Power of Attorney: The patent practitioners associated with Customer Number 000061297.

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/US04/31789 09/29/2004 which claims benefit of 60/506,149 09/29/2003

Foreign Applications

If Required, Foreign Filing License Granted: 02/15/2007

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is US10/573,905

Projected Publication Date: 06/07/2007

Non-Publication Request: No

MAR 2 6 2007 S. Martine/

#### Early Publication Request: No

Title

Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions

#### **Preliminary Class**

514

## PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process simplifies the filing of patent applications on the same invention in member countries, but does not result in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

# LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

#### **GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upor, written notification. The

date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

#### **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



#### United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS

APPL NO.	FILING OR 371(c) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	TOT CLMS	IND CLMS
		40.45	4=00	MEDOO 4 404 IIO	20	4

10/573,905

05/30/2006

1647 1730 WP03-1 A04-US

WARREN PHARMACEUTICALS. INC 712 KITCHAWAN ROAD OSSINING, NY 10562



CONFIRMATION NO. 2092

\*OC000000022649269\*

Date Mailed: 03/13/2007

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

#### Applicant(s)

Thomas Coleman, Mt. Kisco, NY: Osman Yilmaz, Gottepe, TURKEY;

#### Assignment For Published Patent Application

The Kenneth S. Warren Institute, Inc., Ossining, NY Warren Pharmaceuticals, Inc., Ossining, NY

Power of Attorney: The patent practitioners associated with Customer Number 000061297.

#### Domestic Priority data as claimed by applicant

This application is a 371 of PCT/US04/31789 09/29/2004 which claims benefit of 60/506,149 09/29/2003

#### Foreign Applications

If Required, Foreign Filing License Granted: 02/15/2007

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is US10/573,905

Projected Publication Date: 06/07/2007

Non-Publication Request: No

Early Publication Request: No

**Title** 

Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions

**Preliminary Class** 

514

#### PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process simplifies the filing of patent applications on the same invention in member countries, but does not result in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

#### **GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The

date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

#### **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).





PTO/SB/01A (10-05) Approved for use through 07/31/2006. OMB 0651-0032 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

## DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN **APPLICATION DATA SHEET (37 CFR 1.76)**

Title of Invention	TISSUE PROTECTIVE CYTOKINES FOR THE TREATMENT AND PREVENTION OF SEPSIS AND THE FORMATION OF ADHESIONS				
As the belo	w named inventor(s), I/we declare that:				
This declar	ation is directed to:				
	▼ The attached application, or				
	Application Nofiled on				
	As amended on(if applicable);				
sought;	e that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is				
I/we have namendmen	reviewed and understand the contents of the above-identified application, including the claims, as amended by any at specifically referred to above;				
material to became av	wledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which vailable between the filing date of the prior application and the national or PCT International filing date of the prior application.				
Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.  All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any					
FULL NAM	IE OF INVENTOR(S)				
Inventor one: MICHAEL BRINES					
Signature:	the state of the s				
Inventor tw	io: ANTHONY CERAMI				
Signature:	Citizen of: US				
Addit	ional inventors or a legal representative are being named on1additional form(s) attached hereto.				
This selication	n of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file				

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete. including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer. U.S. Patent and Trademark Office. U.S. Department of Commerce. P.C. Box 1450. Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need essistance in completing the form. call 1-800-PTO-9199 and select option 2.



			Aparoved for u	PTO/SB/02A (09-04) use through 07/31/2006. OMB 0651-0032	
Under the Paperwork Reduction Act of 1995, no person	is are required to res	spond to a collection	nt and Trademark Office on of information unless	e; U.S. DEPARTMENT OF COMMERCE s it contains a valid OMB control number.	
DECLARATION		ADDITION/ Supplementa	AL INVENTOR(3	S)  Page 2 of 2	
Name of Additional Joint Inventor, if any	<i>y</i> :	A petitio	on has been filed for	this unsigned inventor	
Given Name (first and middle (if any))		Family Name (	or Sumame		
Thomas		Coleman			
inventor's Signature Thomas Menn				Date 3/27/06	
Mt. Kisco Residence: City	NY State	us C	Country	us Citizenship	
20 Emery Road				,	
Mailing Address					
Mt. Kisco	NY		10549	US	
City	State		Zip	Country	
Name of Additional Joint Inventor, if any	<i>/</i> :	A petitic	on has been filed for	this unsigned inventor	
Given Name (first and middle (if any))	1	Family Name or Sumame			
Osman		Yilmaz		· · · · · · · · · · · · · · · · · · ·	
Inventor's Signature				Date	
Gottepe	lzmir		TR	TR	
Residence: City	State		Country	Citizenship	
100 Sokad Kalaci, Apt. 24/17			-		
Gottepe	Izmir			TR	
City	State		Zip	Country	
Name of Additional Joint Inventor, if any	<i>y</i> :	A petitio	on has been filed for	rthis unsigned inventor	
Given Name (first and middle (if any))		Family Name or Sumame			
Inventor's Signature				Date	
			0	Citizonahia	
Residence: City	State		Country	Citizenship	
Mailing Address					

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retains a penefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 21 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTC-9199 (1-806-9199) and select option 2.

PTO/SB/01A (10-05)

Approved for use through 07/31/206 (10-05)

Approved for use through 07/31/206 (0B 0551-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

## DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN **APPLICATION DATA SHEET (37 CFR 1.76)**

Title of Invention	TISSUE PROTECTIVE CYTOKINES FOR THE TREATMENT AND PREOF SEPSIS AND THE FORMATION OF ADHESIONS	EVENTION			
As the belo	low named inventor(s), I/we declare that:				
This declar	aration is directed to:				
	☑ The attached application, or				
	Application No filed on				
		(if applicable);			
i/we believe sought;	we that I/we am/are the original and first inventor(s) of the subject matter which is claimed and fo	r which a patent is			
I/we have r amendmen	reviewed and understand the contents of the above-identified application, including the claims, a ent specifically referred to above;	s amended by any			
material to became av	sowiedge the duty to disclose to the United States Patent and Trademark Office all information know patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material available between the filing date of the prior application and the national or PCT international lon-in-part application.	I II I O I I I I I I I I I I I I I I I			
	WARNING:	•			
contribute numbers (of the USPTC) them to the publication or issuance application authorizatic publicly available.	Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.				
to be true, a punishable	nents made herein of my/own knowledge are true, all statements made herein on information and to b, and further that these statements were made with the knowledge that willful false statements and the by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the a suing thereon.	i ilia iive are			
	ME OF INVENTOR(S)				
Inventor on	one: MICHAEL BRINES	<del></del>			
Signature:	: Miles Smit. Citizen of: US				
Inventor tw	two: ANTHONY CERAMI				
Signature:		Mark ad barria			
	litional inventors or a legal representative are being named on1 additional form(s) a				
(and by the U minute to com case. Any con	ton of Information is required by 35 U.S.C. 115 and 37 CFR 1.83. The information is required to obtain or retain a benefit by USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collectiful complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary deper comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, strouble be sent. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND OTHIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.	rding upon the individual to the Chief Information			

W00039500

DECLARATION		Supplemen	· · · · · · · · · · · · · · · · · · ·	)R(S) Pas	
Name of Additional Joint Inventor, if an		1	ition has been tiled	i for this unsigned	Inventor
Chan Name (first and middle (if any) Thomas	Coleman	e or Surname			
inventor's Signature		<u>.</u>		Date	
VII. Klaco Residence: City	NY State		US Country	US Citize	enship
20 Emery Road					•
Mailing Address	<del></del>				•
ML Kisce City	NY State		10549 Zip	US Coun	try
Name of Additional Joint Inventor, if an	y:	A pet	ition has been filed	i for this unsigned	inventor
Given Name (first and middle (if any	))	Family Name or Surname			
Osman		Yümaz			
Inventor's Signature				Date	
Gottepe	tzmir State		TR Country		TR Citizenship
Residence: City 100 Sokad Kalaci, Apt. 24/17	Jiane		) Ocano		
Mailing Address	T .		···	TR	······································
City	Izmir State		Zip	Cour	itry
Name of Additional Joint Inventor, if an	y:	A pet	ition has been file	d for this unsigned	I inventor
Given Name (first and middle (if any)	)	Family Name or Surname			
				·····	
Inventor's Signature				Date	
Residence: City	State		Country		Citizenship
				•	
Mailing Address	<u> </u>				<u> </u>
City This coSection of Information is required by 35 U.S.C. 115	State		Zip	Cour	ntry

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 21 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

. (4







PTO/SE/01A (19-05)

Approved for use through 07/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

## DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	TISSUE PI OF SEPSI	ROTECT S AND T	IVE CYTOKII HE FORMAT	NES FOR TH	HE TREATME HESIONS	ENT AND PR	EVENTION
As the belo	w named inven	itor(s), l/we	declare that:				
This declar	ation is directed	d to:					
			hed application, o				
	· $\square$	Application	on No	fik	ed on		
			As amended on _				
sought;							r which a patent is
amendmen	it specifically re	ferred to ab	ove;				s amended by any
material to became av continuatio	patentability a: /ailable betwee n-in-part applic	s defined in an the filing ation.	date of the prior	r application and	i the national or	PCT Internationa	own to me/us to be I information which I filing date of the
Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by numbers (other than a check or credit card authorization or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.							
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.							
FULL NAM	E OF INVENT	OR(S)					
inventor or	18: MICHAEL B	RINES					
Signature:	Mu	bul	forme.		Citizen o	r us	
Inventor ty	vo: .ANTHONY (	CERAMI			<del> </del>		
Ciamatana.					Citizen o	f: <u>US</u>	
Addit	lonal inventors or	a legal repre	sentative are being	named on	1	additional form(s)	attached hereto.
	-4 l-4-metten by	navirad by 36	U.S.C. 115 and 37 CF	R 1.63. The informati	on is required to obtain	n or retain a benefil by	the public which is to file

This collection of information is required by 35 U.S.C. 116 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual minute to complete, including gathering, preparing, and submitting the complete time suggestions for reducing this burden, should be sent to the Chief information case. Any comments on the amount of time you require to complete ins form and/or suggestions for reducing this burden, should be sent to the Chief information case. Any comments on the amount of time you require to complete from suggestions for reducing this burden, should be sent to the Chief information case. Any comments on the unspection of time will vary depending upon the individual minute to complete time to the USPTO. Box 1450, Alexandria, VA 22313-1450. FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

· 🙀






107.000 OMB 0001-0002 107.000 OMB 0001-0002 107.0000 OMB 0001-0002

- COLADA TION! Supplemental Shoot DECLARATION A petition has been filed for this unsigned inventor Name of Additional Joint Inventor, if any: Family Name or Sumame Chan Mann (first and middle (ff greet)) Coleman Thomas Inventor's Date Signature US US. Citizenship Country State Residence: City 20 Emery Road Malling Address 10549 US NY MR KISCO Country Zlp State City A petition has been filed for this unsigned inventor Name of Additional Joint Inventor, if any: Family Name or Surname Given Name (first and middle (if any)) Оаптал Inventor's Signature TR TR bzmir Country Citizenship State Residence: City 100 Soked Kalaci, Apt. 24/17 Malling Address TR izmir Gotteen Country ΖΦ State City Name of Additional Joint Inventor, if any: A petition has been filed for this unsigned inventor Family Name or Sumame Given Name (first and middle (if any)) inventor's Date Signature Citizenship Country State Residence: City Mailing Address Country State

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to fits (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 21 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual minutes to complete, including gathering, preparing, and submitting the completed application from to the USPTO. Time will vary depending upon the individual manual of time you require to complete this form end/or suggestions for reducing this turden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-785-9199) and select option 2.



## APPLICATION DATA SHEET

## **Application Information**

Application Type:: Regular

Subject Matter:: Utility

Suggested Classification:: 514/2,8; 530/351,397,399

Suggested Group Art Unit:: 1646

CD-Rom or CD-R?:: None

TITLE:: TISSUE PROTECTIVE CYTOKINES FOR THE

TREATMENT AND PREVENTION OF SEPSIS

AND THE FORMATION OF ADHESIONS

Attorney Docket Number:: WP03-1A04-US

Request for Early Publication:: No

Request for Non-Publication:: No

Suggested Drawing Figure:: 1

Total Drawing Sheets:: 9

Small Entity:: No

Petition Included?:: No

Secrecy Order in Parent Appl.?:: No

## **Applicant Information**

Applicant Authority Type:: Inventor

Primary Citizenship:: US

Country:: US

Status:: Full Capacity

Given Name:: Michael

Middle Name::

Family Name:: Brines

Name Suffix::

City of Residence::

Woodbridge

State or Providence of Residence::

CT

Country of Residence::

US

Street of Mailing Address::

1 Wepawaug Road

City of Mailing Address::

Woodbridge

State or Providence of Mailing Address:: CT

Country of Mailing Address::

US

Postal or Zip Code of Mailing Address:: 06525

Applicant Authority Type::

Inventor

Primary Citizenship::

US

Country::

US

Status::

**Full Capacity** 

Given Name::

Anthony

Middle Name::

Family Name::

Cerami

Name Suffix::

City of Residence::

Somers

State or Providence of Residence::

NY

Country of Residence::

US

Street of Mailing Address::

58A Heritage Hill Road

City of Mailing Address::

Somers

State or Providence of Mailing Address:: NY

Country of Mailing Address::

US

Postal or Zip Code of Mailing Address:: 10589

Applicant Authority Type::

Inventor

Primary Citizenship::

US

Country::

US

Status::

**Full Capacity** 

Given Name::

Thomas

Middle Name::

Family Name::

**COLEMAN** 

Name Suffix::

City of Residence::

Mt. Kisco

State or Providence of Residence::

NY -

Country of Residence::

US

Street of Mailing Address::

20 Emery Street

City of Mailing Address::

Mt. Kisco

State or Providence of Mailing Address:: NY

Country of Mailing Address::

US

Postal or Zip Code of Mailing Address:: 10549

Applicant Authority Type::

Inventor

Primary Citizenship::

TR

Country::

TR

Status::

**Full Capacity** 

Given Name::

Osman

Middle Name::

Family Name::

YILMAZ

Name Suffix::

City of Residence::

Gottepe

State or Providence of Residence::

**Izmir** 

Country of Residence::

TR

Street of Mailing Address::

100 Sokad Kalaci, Apt. 24/17

City of Mailing Address::

Gottepe

State or Providence of Mailing Address:: Izmir

Country of Mailing Address::

TR



## Postal or Zip Code of Mailing Address::

## Correspondence Information

Correspondence Customer

000061297

Number::

Phone Number::

(914)762-7586 ext. 207

Fax Number::

(914)762-7292

E-mail Address::

fhamble@warrenpharma.com

## Representative Information

Representative Customer	000061297	
Number::		

## **Domestic Priority Information**

Application::	Continuity Type::	Parent Application::	Parent Filing Date::
This Application	National Stage of	PCT/US04/31789	09/29/04
PCT/US04/31789	An application claiming	60/506,149	09/29/03
	the benefit under 35		
	USC 119(e)		

. 🙌

## **Assignee Information**

Assignee name::

The Kenneth S. Warren Institute, Inc.

Street of mailing

712 Kitchawan Road

address::

City of mailing address::

Ossining

State or Province of

NY

Mailing address::

Country of mailing

US

address::

Postal or Zip Code of

10562

mailing address::

Assignee name::

Warren Pharmaceuticals, Inc.

Street of mailing

712 Kitchawan Road

address::

City of mailing address::

Ossining

State or Province of

NY

Mailing address::

Country of mailing

US

address::

Postal or Zip Code of

10562

mailing address::



Express Mail No.: *EV 913 329 673 US* 

## THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Coleman et al.

Confirmation No.: 2092

Serial No.: 10/573,905

Art Unit: 1647

371(c) Date: May 30, 2006

Examiner: DeBerry, Regina M.

For:

TISSUE PROTECTIVE CYTOKINES FOR THE

TREATMENT AND PREVENTION OF SEPSIS

AND THE FORMATION OF ADHESIONS

Attorney Docket No: 10165-042-999

Formerly: WP03-1 A04-US

#### TRANSMITTAL OF REVOCATION AND POWER OF ATTORNEY

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

Applicants submit herewith a Revocation And Power Of Attorney executed by Carla Cerami Hand on June 15, 2007, on behalf of The Kenneth S. Warren Institute, Inc. coassignee with Warren Pharmaceuticals, Inc. of the above-identified patent application. Applicants further submit herewith a Revocation And Power Of Attorney executed by Carla Cerami Hand on September 11, 2007, of Warren Pharmaceuticals, Inc. co-assignee with The Kenneth S. Warren Institute, Inc..

Applicants request that the Revocations And Powers Of Attorney be made of record in the file of the above-identified patent application.

It is estimated that no fee is due in connection with this transmittal. In the event that a fee is required, please charge the required fee to Jones Day Deposit Account No. 50-3013. A copy of this sheet is enclosed for accounting purposes.

Respectfully submitted, by: School han Kathnick Bug. No. 52,413

Laure A. Correct 30,742

Date:

October 16, 2007

JONES DAY

222 East 41st Street

New York, New York 10017

(212) 326-3939



#### **POWER OF ATTORNEY**

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Coleman et al.

Confirmation No.: 2092

Serial No.: 10/573,905

Art Unit: 1647

371(c) Date: May 30, 2006

Examiner: To Be Assigned

For:

TISSUE PROTECTIVE CYTOKINES FOR THE TREATMENT AND PREVENTION OF SEPSIS

Attorney Docket No: 10165-042-999

AND THE FORMATION OF ADHESIONS

Formerly: WP03-1 A04-US

## REVOCATION AND POWER OF ATTORNEY

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The Kenneth S. Warren Institute, Inc. (partial assignee) hereby revokes any and all previous powers and appoints:

Practitioners of Jones Day associated with at Customer Number 20583

to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please direct all correspondence address for the above-identified application to:

The above mentioned Customer Number.

Address: Jo

Jones Day, 222 East 41st Street, New York, New York 10017

Telephone: (2

(212) 901-9028

## Statement Under 37 C.F.R. 3.73(b)

The Kenneth S. Warren Institute, Inc. is a partial assignee. The Kenneth S. Warren Institute, Inc. and Warren Pharmaceuticals, Inc. together own the entire right, title and interest in the above-identified application by virtue of assignments from the inventors. See 37 C.F.R. §3.71 (Statement Under 37 C.F.R. §3.73(b) is applicable.)

1.

-1-

in the patent application/patent identified above by virtue of either: Assignments from co-inventors Michael Brines, Anthony Cerami, and Thomas  $\boxtimes$ Coleman of the above-identified application. The assignments were recorded in the United States Patent and Trademark Office on March 29, 2006 at Reel 017762, Frame 0927. OR A chain of title from the inventor(s) of the patent application/patent identified above, to the current assignee as shown below: To: From: The document was recorded in the United States Patent and Trademark Office , Frame , or for which a copy thereof is attached. Additional documents in the chain of title are listed on a supplemental sheet. Copies of assignments or other documents in the chain of title are attached. [Note: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08] The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee. ASSIGNEE: The Kenneth S. Warren Institute, Inc. Date: Signature: Position/Title: Note: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required.

16

Total of 2 forms are submitted.



#### POWER OF ATTORNEY

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Coleman et al.

Confirmation No.: 2092

Serial No.: 10/573,905

Art Unit: 1647

371(c) Date: May 30, 2006

Examiner: To Be Assigned

For:

TISSUE PROTECTIVE CYTOKINES FOR THE

Attorney Docket No: 10165-042-999

TREATMENT AND PREVENTION OF SEPSIS AND THE FORMATION OF ADHESIONS

Formerly: WP03-1 A04-US

## REVOCATION AND POWER OF ATTORNEY

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Warren Pharmaceuticals, Inc. (partial assignee) hereby revokes any and all previous powers and appoints:

Practitioners of Jones Day associated with at Customer Number 20583

to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please direct all correspondence address for the above-identified application to:

The above mentioned Customer Number.  $\boxtimes$ 

Firm or Individual Name: X

Address:

Jones Day, 222 East 41st Street, New York, New York 10017

Telephone:

(212) 901-9028

#### Statement Under 37 C.F.R. 3.73(b)

Warren Pharmaceuticals, Inc. is a partial assignee. Warren Pharmaceuticals, Inc. and the Kenneth S. Warren Institute, Inc. together own the entire right, title and interest in the above-identified application by virtue of assignments from the inventors. See 37 C.F.R. §3.71 (Statement Under 37 C.F.R. §3.73(b) is applicable.)

in the patent application/patent identified above by virtue of either: Assignment from the co-inventor Osman Yilmaz of the above-identified application. The assignment to Warren Pharmaceuticals, Inc. was recorded in the United States Patent and Trademark Office on May 31, 2006 at Reel 017930, Frame 0171. OR A chain of title from the inventor(s) of the patent application/patent identified above, to the current assignee as shown below: From: To: The document was recorded in the United States Patent and Trademark Office , or for which a copy thereof is at Reel , Frame on attached. Additional documents in the chain of title are listed on a supplemental sheet. Copies of assignments or other documents in the chain of title are attached. Note: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08] The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee. ASSIGNEE: Warren Pharmaceuticals, Inc. Typed Name: Position/Title: Note: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required.

☐ Total of 2 forms are submitted.

Express Mail No.: EV 913 329 673 US

PTO/SB/122 (04-05) Approved for use through 07/31/2006. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## CHANGE OF CORRESPONDENCE ADDRESS Application

Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Application Number	10/573,903
Filing Date	May 30, 2006
First Named Inventor	Thomas Coleman
Art Unit	1647
Examiner Name	DeBerry, Regina M.
Attorney Docket Number	10165-042-999

Please chan	ge the Correspondence Ad	ddress for the above	-identified pate	ent application	ı to:
	dress associated with ner Number:	20583			
OR					
Firm or Individu	ual Name Jones Day	·			
Address 22	22 East 41st Street				
City Ne	w York		State NY		Zip <sub>10017</sub>
Country Uni	ited States	<u> </u>			
Telephone (2	212) 901-9028		Email		
	nnot be used to change the				change the r Data Change" (PTO/SB/124).
I am the:			4		
	Applicant/Inventor				
	Assignee of record of the Statement under 37 CFF		. (Form PTO/S	SB/96).	
✓	Attorney or agent of reco	ord. Registration Nur	nber <u>30,742</u>		·
	Registered practitioner named in the application transmittal letter in an application without an executed oath or declaration. See 37 CFR 1.33(a)(1). Registration Number				
Signature	Caura A.	Correri	6g:.	Deg. No	an Hathrell 5. 52,413
Typed or Printed Name	Laura A. Coruzzi			4	
Date October 16, 2007 Telephone (212) 326-3939					
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.					
*Total of 1	forms are submitted.				

This collection of information is required by 37 CFR 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.